mbs303MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. TheMBS-303: a CD20 inhibitors, CD3 stimulants Drug, Initially developed by Beijing Mabworks Biotech Co., Ltd.,